Hwa-Jin Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hwa-Jin Park has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Dong-Ha Lee
Department of Biomedical Laboratory Science, Korea Nazarene University, Chungnam 31172, Korea
15 shared publicationsHyun-Jeong Cho
Department of Biomedical Laboratory Science, College of Medical Science, Konyang University, Daejeon, Korea
13 shared publications- Man Hee Rhee
College of Veterinary Medicine, Kyungpook National University, Daegu 41566, Republic of Korea
13 shared publications Hyun-Hong Kim
Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering, Inje University, Gimhae, Gyungnam 50834, Korea
12 shared publicationsHyuk-Woo Kwon
Department of Biomedical Laboratory Science, Far East University, Eumseong, Republic of Korea
11 shared publicationsJung-Hae Shin
Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering, Inje University, Gimhae, Republic of Korea
9 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5326
Polyphenol-Rich Oenanthe javanica as a Cardioprotective Functional Food Candidate Exhibiting Antiplatelet Activity via Suppression of Ca2+ Mobilization and Thromboxane A2 Production
Polyphenol-rich Oenanthe javanica (Blume) DC. is widely consumed in Asia but its impact on platelet activation, a cause of cardiovascular disease (CVD), is unclear. Collagen-driven platelet activation requires intracellular Ca2+ mobilization and thromboxane A2 (TXA2) production—rational targets for CVD prevention. A hot water extract of O. javanica (OJWE) was profiled by HPLC and tested on collagen-stimulated washed human platelets. Aggregation, Fura-2 [Ca2+]i, and TXB2 were measured, including combinations with verapamil, aspirin, caffeic acid (CA), and chlorogenic acid (CGA). Coagulation (PT/APTT) and ex vivo effects in Sprague–Dawley rats given OJWE (1 or 5 mg day−1, 30 days) were also evaluated. OJWE dose-dependently inhibited collagen-induced aggregation in a Ca2+-dependent manner, synergizing with verapamil, and suppressed [Ca2+]i mobilization and TXA2 production. CA and CGA synergistically enhanced aspirin-mediated COX-1 inhibition. PT/APTT were unaffected in vitro and ex vivo. Dietary OJWE modestly but significantly reduced rat platelet aggregation without altering coagulation. OJWE attenuates platelet activation by selectively targeting Ca2+ mobilization and TXA2 biosynthesis without compromising hemostasis, supporting O. javanica as a functional food with cardiovascular potential at dietary intake.
- 12 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5326
Open AccessPolyphenol-Rich Oenanthe javanica as a Cardioprotective Functional Food Candidate Exhibiting Antiplatelet Activity via Suppression of Ca2+ Mobilization and Thromboxane A2 Production
Polyphenol-rich Oenanthe javanica (Blume) DC. is widely consumed in Asia but its impact on platelet activation, a cause of cardiovascular disease (CVD), is unclear. Collagen-driven platelet activation requires intracellular Ca2+ mobilization and thromboxane A2 (TXA2) production—rational targets for CVD prevention. A hot water extract of O. javanica (OJWE) was profiled by HPLC and tested on collagen-stimulated washed human platelets. Aggregation, Fura-2 [Ca2+]i, and TXB2 were measured, including combinations with verapamil, aspirin, caffeic acid (CA), and chlorogenic acid (CGA). Coagulation (PT/APTT) and ex vivo effects in Sprague–Dawley rats given OJWE (1 or 5 mg day−1, 30 days) were also evaluated. OJWE dose-dependently inhibited collagen-induced aggregation in a Ca2+-dependent manner, synergizing with verapamil, and suppressed [Ca2+]i mobilization and TXA2 production. CA and CGA synergistically enhanced aspirin-mediated COX-1 inhibition. PT/APTT were unaffected in vitro and ex vivo. Dietary OJWE modestly but significantly reduced rat platelet aggregation without altering coagulation. OJWE attenuates platelet activation by selectively targeting Ca2+ mobilization and TXA2 biosynthesis without compromising hemostasis, supporting O. javanica as a functional food with cardiovascular potential at dietary intake.
- Open Access
- 27 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2254
Antithrombotic Effects of Cordycepin-Enriched WIB-801CE via Inhibition of Thromboxane A2-Induced αIIbβ3 Activation and Thrombin-Mediated Fibrin Clot Retraction
WIB-801CE, a standardized Cordyceps militaris extract containing 7.0% cordycepin, suppresses platelet activation induced by thrombin, collagen, and adenosine diphosphate (ADP). As these agonists generate thromboxane A2 (TXA2), which amplifies platelet activation via a self-propagating feedback loop, blockade of TXA2-mediated signaling offers strong antithrombotic potential. TXA2-antagonistic effects were evaluated using U46619, a stable TXA2 analog. Platelet activation was assessed by fibrinogen binding to integrin αIIbβ3, aggregation, and phosphorylation of platelet-activating proteins—PI3K (Tyr458), Akt (Ser473), p38 MAPK (Thr180/Tyr182), ERK1 (Thr202/Tyr204), JNK1 (Thr183/Tyr185)—and inhibitory proteins—VASP (Ser157) and IP3RI (Ser1756)—via immunoblotting. Thrombin-induced fibrin clot retraction, cytotoxicity, coagulation parameters, and antioxidant capacity were also examined. WIB-801CE significantly inhibited U46619-induced fibrinogen binding to integrin αIIbβ3 and platelet aggregation, without inducing cytotoxicity or impairing hemostatic function. It also significantly downregulated the phosphorylation of platelet-activating proteins and upregulated the phosphorylation of platelet-inhibiting proteins. Additionally, WIB-801CE abolished thrombin-induced fibrin clot retraction and demonstrated antioxidant capacity. WIB-801CE disrupts TXA2-driven platelet activation and thrombus stabilization by selectively modulating phosphorylation of key signaling proteins at defined regulatory sites. These properties highlight its promise as a therapeutic candidate for thrombotic disorders with platelet hyperreactivity.
- 27 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2254
Open AccessAntithrombotic Effects of Cordycepin-Enriched WIB-801CE via Inhibition of Thromboxane A2-Induced αIIbβ3 Activation and Thrombin-Mediated Fibrin Clot Retraction
WIB-801CE, a standardized Cordyceps militaris extract containing 7.0% cordycepin, suppresses platelet activation induced by thrombin, collagen, and adenosine diphosphate (ADP). As these agonists generate thromboxane A2 (TXA2), which amplifies platelet activation via a self-propagating feedback loop, blockade of TXA2-mediated signaling offers strong antithrombotic potential. TXA2-antagonistic effects were evaluated using U46619, a stable TXA2 analog. Platelet activation was assessed by fibrinogen binding to integrin αIIbβ3, aggregation, and phosphorylation of platelet-activating proteins—PI3K (Tyr458), Akt (Ser473), p38 MAPK (Thr180/Tyr182), ERK1 (Thr202/Tyr204), JNK1 (Thr183/Tyr185)—and inhibitory proteins—VASP (Ser157) and IP3RI (Ser1756)—via immunoblotting. Thrombin-induced fibrin clot retraction, cytotoxicity, coagulation parameters, and antioxidant capacity were also examined. WIB-801CE significantly inhibited U46619-induced fibrinogen binding to integrin αIIbβ3 and platelet aggregation, without inducing cytotoxicity or impairing hemostatic function. It also significantly downregulated the phosphorylation of platelet-activating proteins and upregulated the phosphorylation of platelet-inhibiting proteins. Additionally, WIB-801CE abolished thrombin-induced fibrin clot retraction and demonstrated antioxidant capacity. WIB-801CE disrupts TXA2-driven platelet activation and thrombus stabilization by selectively modulating phosphorylation of key signaling proteins at defined regulatory sites. These properties highlight its promise as a therapeutic candidate for thrombotic disorders with platelet hyperreactivity.
- Open Access
- 22 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2579
Theophylline Attenuates the Release of Cardiovascular Disease-Related Triglyceride and Cholesterol by Inhibiting the Activity of Microsomal Triglyceride Transfer Protein in Rat Hepatocytes
Background/Objectives: Cardiovascular diseases (CVD) remain the leading cause of diet-related mortality, with hepatic overproduction of very-low-density lipoprotein (VLDL) being a central driver of dyslipidemia. The microsomal triglyceride transfer protein (MTP) is essential for this process, and its activity is negatively regulated by cyclic adenosine monophosphate (cAMP). Theophylline, a methylxanthine found in tea, increases intracellular cAMP. This study aimed to evaluate whether physiologically relevant concentrations of theophylline could beneficially modulate lipoprotein secretion in an ex vivo model of diet-induced MTP activation. Methods: Primary hepatocytes were isolated from rats fed a high-fat, high-carbohydrate diet (HFCD). Cells were treated with 100 µM theophylline, and the secretion of triglyceride (TG), total cholesterol (TC), VLDL-cholesterol (VLDL-C), and HDL-cholesterol (HDL-C) was quantified. Hepatocellular MTP activity and atherogenic indices were also assessed. Results: Compared to untreated control cells, theophylline treatment significantly reduced the secretion of TG by 6% and TC by 24%. Specifically, VLDL-C secretion decreased by 6%, while HDL-C secretion increased substantially by 93%. These lipid-modulating effects were correlated with a 6.9% reduction in MTP activity. Consequently, significant improvements were observed in the atherogenic indices TG/HDL-C, TC/HDL-C, and the atherogenic index (AI) (p < 0.01). Conclusions: Our findings demonstrate that physiologically attainable concentrations of theophylline rebalance lipoprotein secretion by suppressing hepatic MTP activity, shifting the lipid profile toward an anti-atherogenic state. These results highlight the potential of theophylline as a functional dietary component for mitigating diet-induced dyslipidemia and reducing cardiovascular risk.
- 22 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2579
Open AccessTheophylline Attenuates the Release of Cardiovascular Disease-Related Triglyceride and Cholesterol by Inhibiting the Activity of Microsomal Triglyceride Transfer Protein in Rat Hepatocytes
Background/Objectives: Cardiovascular diseases (CVD) remain the leading cause of diet-related mortality, with hepatic overproduction of very-low-density lipoprotein (VLDL) being a central driver of dyslipidemia. The microsomal triglyceride transfer protein (MTP) is essential for this process, and its activity is negatively regulated by cyclic adenosine monophosphate (cAMP). Theophylline, a methylxanthine found in tea, increases intracellular cAMP. This study aimed to evaluate whether physiologically relevant concentrations of theophylline could beneficially modulate lipoprotein secretion in an ex vivo model of diet-induced MTP activation. Methods: Primary hepatocytes were isolated from rats fed a high-fat, high-carbohydrate diet (HFCD). Cells were treated with 100 µM theophylline, and the secretion of triglyceride (TG), total cholesterol (TC), VLDL-cholesterol (VLDL-C), and HDL-cholesterol (HDL-C) was quantified. Hepatocellular MTP activity and atherogenic indices were also assessed. Results: Compared to untreated control cells, theophylline treatment significantly reduced the secretion of TG by 6% and TC by 24%. Specifically, VLDL-C secretion decreased by 6%, while HDL-C secretion increased substantially by 93%. These lipid-modulating effects were correlated with a 6.9% reduction in MTP activity. Consequently, significant improvements were observed in the atherogenic indices TG/HDL-C, TC/HDL-C, and the atherogenic index (AI) (p < 0.01). Conclusions: Our findings demonstrate that physiologically attainable concentrations of theophylline rebalance lipoprotein secretion by suppressing hepatic MTP activity, shifting the lipid profile toward an anti-atherogenic state. These results highlight the potential of theophylline as a functional dietary component for mitigating diet-induced dyslipidemia and reducing cardiovascular risk.
- 1 November 2020
- Published by Elsevier in Thrombosis Research
- Vol. 195, 87-94
The antithrombotic effect of caffeic acid is associated with a cAMP-dependent pathway and clot retraction in human platelets
- 1 November 2020
- Published by Elsevier in Thrombosis Research
- Vol. 195, 87-94
The antithrombotic effect of caffeic acid is associated with a cAMP-dependent pathway and clot retraction in human platelets
- Open Access
- 1 April 2019
- Published by Elsevier in Journal of Ginseng Research
- Vol. 43 (2) , 236-241
Inhibitory effects of thromboxane A2 generation by ginsenoside Ro due to attenuation of cytosolic phospholipase A2 phosphorylation and arachidonic acid release
- 1 April 2019
- Published by Elsevier in Journal of Ginseng Research
- Vol. 43 (2) , 236-241
Open AccessInhibitory effects of thromboxane A2 generation by ginsenoside Ro due to attenuation of cytosolic phospholipase A2 phosphorylation and arachidonic acid release
- 1 November 2018
- Published by Springer Nature in Biotechnology and Bioprocess Engineering
- Vol. 23 (6) , 641-648
Caffeic Acid Diminishes the Production and Release of Thrombogenic Molecules in Human Platelets
- 1 November 2018
- Published by Springer Nature in Biotechnology and Bioprocess Engineering
- Vol. 23 (6) , 641-648
Caffeic Acid Diminishes the Production and Release of Thrombogenic Molecules in Human Platelets
- Open Access
- 31 December 2017
- Published by The Korean Society for Biomedical Laboratory Sciences in Biomedical Science Letters
- Vol. 23 (4) , 310-320
Inhibitory Effects of Total Saponin Korean Red Ginseng on Thromboxane A2Production and P-Selectin ExpressionviaSuppressing Mitogen-Activated Protein Kinases
Jung-Hae Shin, Hyuk-Woo Kwon, Man Hee Rhee and Hwa-Jin Park. BSL 2017;23:310-20. https://doi.org/10.15616/BSL.2017.23.4.310
- 31 December 2017
- Published by The Korean Society for Biomedical Laboratory Sciences in Biomedical Science Letters
- Vol. 23 (4) , 310-320
Open AccessInhibitory Effects of Total Saponin Korean Red Ginseng on Thromboxane A2Production and P-Selectin ExpressionviaSuppressing Mitogen-Activated Protein Kinases
Jung-Hae Shin, Hyuk-Woo Kwon, Man Hee Rhee and Hwa-Jin Park. BSL 2017;23:310-20. https://doi.org/10.15616/BSL.2017.23.4.310
- Open Access
- 31 December 2016
- Published by The Korean Society for Biomedical Laboratory Sciences in Biomedical Science Letters
- Vol. 22 (4) , 127-139
Antiplatelet Effects of Cordycepin-Enriched WIB-801CE fromCordyceps militaris: Involvement of Thromboxane A2,Serotonin, Cyclooxygenase-1, Thromboxane A2Synthase,Cytosolic Phospholipase A2
A species of the fungal genus Cordyceps has been used as an ingredient of traditional Chinese medicine. In this study, we prepared cordycepin-enriched WIB-801CE, an ethanol extract from culture solution of Cordyceps militaris-hypha, and evaluated its antiplatelet effects on human platelet aggregation. WIB-801CE dose-dependently inhibited ADP-, collagen-, and thrombin-induced platelet aggregation. These antiplatelet effects by WIB-801CE were associated with the attenuation of thromboxane A 2 (TXA 2) production and serotonin release by ADP, collagen, and thrombin. The inhibition of TXA 2 production by WIB-801CE was due to the inhibition of cyclooxygenase-1, TXA 2 synthase, and cytosolic phospholipase A 2 activity. Therefore, these data suggest that WIB-801CE may be a beneficial component against protection from platelet aggregation-mediated thrombotic disease.
- 31 December 2016
- Published by The Korean Society for Biomedical Laboratory Sciences in Biomedical Science Letters
- Vol. 22 (4) , 127-139
Open AccessAntiplatelet Effects of Cordycepin-Enriched WIB-801CE fromCordyceps militaris: Involvement of Thromboxane A2,Serotonin, Cyclooxygenase-1, Thromboxane A2Synthase,Cytosolic Phospholipase A2
A species of the fungal genus Cordyceps has been used as an ingredient of traditional Chinese medicine. In this study, we prepared cordycepin-enriched WIB-801CE, an ethanol extract from culture solution of Cordyceps militaris-hypha, and evaluated its antiplatelet effects on human platelet aggregation. WIB-801CE dose-dependently inhibited ADP-, collagen-, and thrombin-induced platelet aggregation. These antiplatelet effects by WIB-801CE were associated with the attenuation of thromboxane A 2 (TXA 2) production and serotonin release by ADP, collagen, and thrombin. The inhibition of TXA 2 production by WIB-801CE was due to the inhibition of cyclooxygenase-1, TXA 2 synthase, and cytosolic phospholipase A 2 activity. Therefore, these data suggest that WIB-801CE may be a beneficial component against protection from platelet aggregation-mediated thrombotic disease.
- Open Access
- 7 December 2016
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 16 (1) , 1-19
Antiplatelet and antithrombotic effects of cordycepin-enriched WIB-801CE from Cordyceps militaris ex vivo, in vivo, and in vitro
A species of the fungal genus Cordyceps has been used as a complementary and alternative medicine of traditional Chinese medicine, and its major component cordycepin and cordycepin-enriched WIB-801CE are known to have antiplatelet effects in vitro. However, it is unknown whether they have also endogenous antiplatelet and antithrombotic effects. In this study, to resolve these doubts, we prepared cordycepin-enriched WIB-801CE, an ethanol extract from Cordyceps militaris-hypha, then evaluated its ex vivo, in vivo, and in vitro antiplatelet and antithrombotic effects. Ex vivo effects of WIB-801CE on collagen- and ADP-induced platelet aggregation, serotonin release, thromboxane A2 (TXA2) production and its associated activities of enzymes [cyclooxygenase-1 (COX-1), TXA2 synthase (TXAS)], arachidonic acid (AA) release and its associated phosphorylation of phospholipase Cβ3, phospholipase Cγ2 or cytosolic phospholipase A2, mitogen-activated protein kinase (MAPK) [p38 MAPK, extracellular signal-regulated kinase (ERK)], and blood coagulation time in rats were investigated. In vivo effects of WIB-801CE on collagen plus epinephrine-induced acute pulmonary thromboembolism, and tail bleeding time in mice were also inquired. In vitro effects of WIB-801CE on cytotoxicity, and fibrin clot retraction in human platelets, and nitric oxide (NO) production in RAW264.7 cells or free radical scavenging activity were studied. Cordycepin-enriched WIB-801CE inhibited ex vivo platelet aggregation, TXA2 production, AA release, TXAS activity, serotonin release, and p38 MAPK and ERK2 phosphorylation in collagen- and ADP-activated rat platelets without affecting blood coagulation. Furthermore, WIB-801CE manifested in vivo inhibitory effect on collagen plus epinephrine-induced pulmonary thromboembolism mice model. WIB-801CE inhibited in vitro NO production and fibrin clot retraction, but elevated free radical scavenging activity without affecting cytotoxicity against human platelets. WIB-801CE inhibited collagen- and ADP-induced platelet activation and its associated thrombus formation ex vivo and in vivo. These were resulted from down-regulation of TXA2 production and its related AA release and TXAS activity, and p38 MAPK and ERK2 activation. These results suggest that WIB-801CE has therapeutic potential to treat platelet activation-mediated thrombotic diseases in vivo.
- 7 December 2016
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 16 (1) , 1-19
Open AccessAntiplatelet and antithrombotic effects of cordycepin-enriched WIB-801CE from Cordyceps militaris ex vivo, in vivo, and in vitro
A species of the fungal genus Cordyceps has been used as a complementary and alternative medicine of traditional Chinese medicine, and its major component cordycepin and cordycepin-enriched WIB-801CE are known to have antiplatelet effects in vitro. However, it is unknown whether they have also endogenous antiplatelet and antithrombotic effects. In this study, to resolve these doubts, we prepared cordycepin-enriched WIB-801CE, an ethanol extract from Cordyceps militaris-hypha, then evaluated its ex vivo, in vivo, and in vitro antiplatelet and antithrombotic effects. Ex vivo effects of WIB-801CE on collagen- and ADP-induced platelet aggregation, serotonin release, thromboxane A2 (TXA2) production and its associated activities of enzymes [cyclooxygenase-1 (COX-1), TXA2 synthase (TXAS)], arachidonic acid (AA) release and its associated phosphorylation of phospholipase Cβ3, phospholipase Cγ2 or cytosolic phospholipase A2, mitogen-activated protein kinase (MAPK) [p38 MAPK, extracellular signal-regulated kinase (ERK)], and blood coagulation time in rats were investigated. In vivo effects of WIB-801CE on collagen plus epinephrine-induced acute pulmonary thromboembolism, and tail bleeding time in mice were also inquired. In vitro effects of WIB-801CE on cytotoxicity, and fibrin clot retraction in human platelets, and nitric oxide (NO) production in RAW264.7 cells or free radical scavenging activity were studied. Cordycepin-enriched WIB-801CE inhibited ex vivo platelet aggregation, TXA2 production, AA release, TXAS activity, serotonin release, and p38 MAPK and ERK2 phosphorylation in collagen- and ADP-activated rat platelets without affecting blood coagulation. Furthermore, WIB-801CE manifested in vivo inhibitory effect on collagen plus epinephrine-induced pulmonary thromboembolism mice model. WIB-801CE inhibited in vitro NO production and fibrin clot retraction, but elevated free radical scavenging activity without affecting cytotoxicity against human platelets. WIB-801CE inhibited collagen- and ADP-induced platelet activation and its associated thrombus formation ex vivo and in vivo. These were resulted from down-regulation of TXA2 production and its related AA release and TXAS activity, and p38 MAPK and ERK2 activation. These results suggest that WIB-801CE has therapeutic potential to treat platelet activation-mediated thrombotic diseases in vivo.
- Open Access
- 1 October 2016
- Published by Elsevier in Journal of Ginseng Research
- Vol. 40 (4) , 359-365
Vasodilator-stimulated phosphoprotein-phosphorylation by ginsenoside Ro inhibits fibrinogen binding to αIIb/β3 in thrombin-induced human platelets
- 1 October 2016
- Published by Elsevier in Journal of Ginseng Research
- Vol. 40 (4) , 359-365
Open AccessVasodilator-stimulated phosphoprotein-phosphorylation by ginsenoside Ro inhibits fibrinogen binding to αIIb/β3 in thrombin-induced human platelets